Hu Zheng-Bin, Sun Xin, He Li-Ya
Department of General Pediatrics, Guangzhou Women and Children's Medical Center Affiliated to Guangzhou Medical University, Guangzhou 510623, Guangdong Province, China.
Department of General Pediatrics, Guangzhou Women and Children's Medical Center Affiliated to Guangzhou Medical University, Guangzhou 510623, Guangdong Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Jun;25(3):957-960. doi: 10.7534/j.issn.1009-2137.2017.03.058.
Hemophilia A (Hemophilia A, HA) is an X-linked recessive hereditary coagulation function disorder, the deficiency and dysfunction of blood coagulation were caused by the mutations of gene encoding clotting factor VIII. The treatment of hemophilia A still depends on the replacement therapy with blood coagulation factor. However, the repeated infusion of clotting factor will produce the neutralizing antibody against FVIII, then resulting in one of the serious complications. The reports on the incidence of inhibitor are different at home and abroad. Due to diverse factors, the inhibitors of hemophilia A clotting factor mainly can be divided into genetic and environmental factors, In this review, the inhibitors of hemophilia A clotting factor and their risk factors are briefly summarized.
甲型血友病（Hemophilia A, HA）是一种X连锁隐性遗传性凝血功能障碍，凝血因子VIII编码基因的突变导致血液凝固的缺乏和功能障碍。甲型血友病的治疗仍依赖于凝血因子替代疗法。然而，反复输注凝血因子会产生针对FVIII的中和抗体，进而导致严重并发症之一。国内外关于抑制剂发生率的报道有所不同。由于多种因素，甲型血友病凝血因子抑制剂主要可分为遗传因素和环境因素。在本综述中，简要总结了甲型血友病凝血因子抑制剂及其危险因素。
